Novartis’ remibrutinib became the second oral BTK inhibitor to post positive Phase 3 top-line results in relapsing multiple sclerosis. The readout positions the drug behind Roche’s fenebrutinib in a fast-moving race toward the first BTK inhibitor for this indication. The company’s update arrives as several rivals have struggled with efficacy or liver safety, making tolerability and benefit-risk central to any potential regulatory path. The development intensifies competition among immune-modulating strategies in MS beyond checkpoint blockade and continues a trend of translating pathway-specific biology into oral, scalable regimens.